Laure-Hélène Mercier Appointed Chair of Poxel's Board

Poxel, a biopharmaceutical company based in Lyon, France, announced the appointment of Laure-Hélène Mercier as Chair of the Board of Directors, effective September 3, 2026. Mercier will replace Sophie Jacq Lapointe, who played a key role in restructuring the company's governance and strategy. The transition aims to enhance financial oversight and foster market dialogue.

Mercier brings over twenty years of experience in the biotechnology industry and financial markets, previously serving as Chief Financial Officer at Innate Pharma. She expressed her commitment to supporting rigorous financial management and governance excellence at Poxel.

The appointment awaits ratification at Poxel's next Annual General Meeting. Lapointe expressed confidence in Mercier's ability to guide Poxel through its next phase, emphasizing the importance of financial discipline and execution for value creation.